Proportion of participants avoiding transfusions while receiving danicopan as an add-on therapy. The number of participants achieving transfusion avoidance are expressed as a percent relative to the total participants in the corresponding treatment group. Corresponding n values are shown at the base of each data point. ∗∗∗P ≤ .001. ∗Defined as participants who remain transfusion free and did not require a transfusion per protocol-specified guidelines. ^†Participants who were RBC transfusion free during the 24 weeks before receiving study drug. ^‡P values are only available for week 12 or TP1.